at Oakland, California and other locations
study started
estimated completion
Paul Harmatz



The primary objective of this study is to establish the natural history of Farber disease (acid ceramidase deficiency) through the collection and analysis of retrospective and prospective data on patients diagnosed with Farber disease. All patients diagnosed with Farber disease are eligible, including both those who have and have not undergone hematopoietic stem cell transplantation (HSCT). Additionally, data and records from deceased patients will provide valuable retrospective data for this study. The secondary objective of the study is to establish a set of clinical data, laboratory data (biomarkers), and functional data potentially useful for: - Assessing the efficacy of HSCT and the efficacy of potential future therapies (for example with RVT-801, recombinant human acid ceramidase) in Farber disease - Characterizing changes in symptoms of patients over time - Characterizing distinct groups (phenotypes) within the patient population - Documenting the disease histories of individual patients to serve as intra-subject control data for those who may enroll in any future clinical studies with therapies for Farber disease The exploratory objectives of the study are: - To explore the relationship between patient disease activity or phenotype and specific ceramide levels or specific immunologic markers (cytokines/chemokines) in blood - To evaluate a standardized tool, the Farber Disease Natural History Instrument (FDNI), to be used for the collection of patient history information, data from clinical, laboratory, genetic, and functional studies, and data from review of medical records

Official Title

Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease


Farber DiseaseFarber's DiseaseFarber LipogranulomatosisAcid Ceramidase DeficiencyCeramidase DeficiencyN-Laurylsphingosine Deacylase DeficiencyASAH1 MutationNatural History StudyObservational StudyProspective StudyRetrospective StudyASAH1Subcutaneous NodulesLysosomal Storage DiseaseLysosomal Storage Disease, Nervous SystemMetabolic DiseasesLipid Metabolism DisordersLipidosesSphingolipidosesGenetic Disease, InbornMusculoskeletal DiseasesConnective Tissue DiseasesCentral Nervous System DiseasesBrain Diseases, Metabolic, InbornBrain Diseases, MetabolicBrain Diseases, InbornBrain DiseasesInfant, Newborn DiseasesInborn Errors of MetabolismInherited Metabolic DiseaseErdheim-Chester Disease


You can join if…

  • Living or deceased subjects with diagnosis of Farber disease, based on clinical (typical clinical symptoms) and biochemical and/or genetic criteria, as follows:
  • Biochemical: An acid ceramidase activity value in white blood cells, cultured skin fibroblasts or other biological sources (e.g., plasma) that is less than 30% of control (normal) values established by the testing laboratory. For deceased subjects only, storage of ceramide in cells from histopathologic sections is also adequate to confirm the diagnosis.
  • Genetic: Nucleotide changes within both alleles of the acid ceramidase gene (ASAH1) or cDNA that indicate, through bioinformatics, gene expression studies, or other methods, a possible loss of function of the acid ceramidase protein.
  • Informed consent or assent, for living subjects. For deceased subjects it is the responsibility of the principal investigator to ensure that the proper requirements are met according to local laws and regulations.

You CAN'T join if...

• Current use or history of use in the past 30 days of an investigational agent (with exception of off-label use of medications).


  • UCSF Benioff Children's Hospital Oaklandaccepting new patients
    OaklandCalifornia94609United States
  • Children's National Health Systemaccepting new patients
    WashingtonDistrict of Columbia20010United States

Lead Scientist


accepting new patients
Start Date
Completion Date
Enzyvant Farber GmbH
Study Type
Last Updated